The Latest Breaking News from Gilead

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To capitalize on the industry’s expansion, it could be wise to invest in fundamentally sound biotech stocks, Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which have the potential to revolutionize medicine. Read…

The drugmaker said its injections were 89 percent more effective than its own Truvada

Gilead Sciences is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit increase.

Gilead Sciences has recently underperformed the broader Nasdaq Composite, but analysts are reasonably bullish about the stock’s outlook.

These three dividend-paying growth stocks are worth a look at current levels as the odds rise for Fed rate cuts.

More than 300 politicians, health experts and celebrities on Thursday called for US pharmaceutical giant Gilead to allow cheap, generic versions of a promising new HIV drug to be produced so it can reach people in developing countries most affected by the deadly disease.

Gilead Sciences has underperformed the broader market YTD, but Wall Street analysts are still cautiously optimistic about the stock’s prospects.

June S&P 500 E-Mini futures (ESM24) are down -0.53%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.87% this morning as a disappointing revenue outlook for the current quarter from Meta weighed on sentiment, while market participants braced for a new round of U.S. economic data and quarterly reports…

Lawsuit against Gilead Sciences raises concerns about innovation impact in drug development and potential implications on future product development.